Journal of the American Society of Nephrology
2008 JASN IMPACT FACTOR 7.505 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on March 18, 2009
Journal of the American Society of Nephrology
© 2009 American Society of Nephrology
doi: 10.1681/ASN.2008060665
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
ASN.2008060665v1
20/4/901    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Austin, H. A.
Right arrow Articles by Balow, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Austin, H. A., III
Right arrow Articles by Balow, J. E.
Related Collections
Right arrowRelated Article

Received June 30, 2008
Accepted on November 16, 2008

CLINICAL RESEARCH

Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy

Howard A. Austin III *1, Gabor G. Illei {dagger}{ddagger}, Michelle J. Braun *, and James E. Balow *

*National Institute of Diabetes and Digestive and Kidney Diseases, {dagger}National Institute of Arthritis and Musculoskeletal and Skin Diseases, and {ddagger}National Institute of Dental and Craniofacial Disorders, National Institutes of Health, Bethesda, Maryland


1 To whom correspondence should be addressed. E-mail: howarda{at}bdg10.niddk.nih.gov.


   Abstract

Patients with lupus membranous nephropathy (LMN) are at substantial long-term risk for morbidity and mortality associated with protracted nephrotic syndrome, including ESRD. The optimal treatment for this condition is controversial. Forty-two patients with LMN participated in a randomized, controlled trial to compare adjunctive immunosuppressive drugs with prednisone alone. Adjunctive regimens included either cyclosporine (CsA) for 11 mo or alternate-month intravenous pulse cyclophosphamide (IVCY) for six doses; the control group received alternate-day prednisone alone. Median proteinuria was 5.4 g/d (range 2.7 to 15.4 g/d). We assessed the primary outcome, time to remission of proteinuria during the 12-mo protocol, by univariate survival analysis. At 1 yr, the cumulative probability of remission was 27% with prednisone, 60% with IVCY, and 83% with CsA. Although both IVCY and CsA were more effective than prednisone in inducing remissions of proteinuria, relapse of nephrotic syndrome occurred significantly more often after completion of CsA than after IVCY. By multivariate survival analysis, treatment with prednisone and high-grade proteinuria (>5 g/d) but not race or ethnicity were independently associated with a decreased probability of remission. Adverse effects during the 12-mo protocol included insulin-requiring diabetes (one with prednisone and two with CsA), pneumonia (one with prednisone and two with CsA), and localized herpes zoster (two with IVCY). In conclusion, regimens containing CsA or IVCY are each more effective than prednisone alone in inducing remission of proteinuria among patients with LMN.


Related Article

Treatment of Membranous Lupus Nephritis: Where Are We Now?
Laurence H. Beck, Jr. and David J. Salant
J. Am. Soc. Nephrol. 2009 20: 690-691. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
L. H. Beck Jr. and D. J. Salant
Treatment of Membranous Lupus Nephritis: Where Are We Now?
J. Am. Soc. Nephrol., April 1, 2009; 20(4): 690 - 691.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP